Long-term follow-up and late complications of CAR-T cell therapy
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e333Keywords:
Survivorship, Receptors, Chimeric Antigen, Screening protocolsAbstract
Background: Chimeric antigen receptor T-cell (CAR-T cell) therapy has transformed the treatment landscape for relapsed or refractory hematologic malignancies. As the number of long-term survivors continues to grow, the recognition and management of late complications have become critical clinical priorities. The existing literature remains fragmented, with limited long-term prospective data and a lack of unified follow-up guidelines. Methods: A narrative review of the literature was conducted using PubMed, MEDLINE, and Google Scholar databases from inception through April 2026. Key search terms included long-term follow-up, survivorship, late effects, CAR-T cell therapy, chimeric antigen receptor, late complications, delayed cytopenias, hypogammaglobulinemia, secondary malignancies, immune reconstitution, and screening. This review synthesizes available evidence with expert consensus recommendations. Results: The review identifies prolonged cytopenias, hypogammaglobulinemia and infectious complications as the most prevalent late effects. Secondary myeloid neoplasms occur with a shorter latency than historically observed after conventional chemotherapy. Neurocognitive deficits following immune effector cell-associated neurotoxicity syndrome generally resolve within six months. Cardiovascular, endocrine, and reproductive late effects are emerging areas of concern with limited specific data. Conclusion: Structured, long-term, multidisciplinary follow-up is essential for CAR-T cell therapy recipients. This review provides recommendations for the long-term surveillance and management of these patients. Prospective registries and standardized screening protocols are urgently needed.
References
1. Bishop MR. Late complications and long-term care of adult CAR T-cell patients. Hematology. 2024; 2024(1): 109–15. https://doi.org/10.1182/hematology.2024000534
2. Brown K, Seftel MD, Hay KA. Innovations en immunothérapie anticancéreuse: thérapie par lymphocytes T porteurs de récepteurs antigéniques chimériques (cellules CAR-T). Can Med Assoc J. 2021; 193(42):E1639–42. https://doi.org/10.1503/cmaj.202907-f
3. Bhaskar ST, Dholaria B, Savani BN, Sengsayadeth S, Oluwole OO. Overview of approved CAR-T products and utility in clinical practice. Clin Hematol Int. 2024;6(4):100–6. https://doi.org/10.46989/001c.124277
4. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307–15. https://doi.org/10.1182/blood.2022018893
5. Puckrin R, Jamani K, Jimenez-Zepeda VH. Long-term survivorship care after CAR-T cell therapy. Eur J Haematol. 2023;112(1):41–50. https://doi.org/10.1111/ejh.14100
6. Cliff ERS, Lafeuille P, Diamond S, Aptekar J, Russler‐Germain DA, Rejeski K, et al. Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients. Blood. 2024;144(S1):2077. https://doi.org/10.1182/blood-2024-203979
7. Chakraborty R, Hill BT, Majeed A, Majhail NS. Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies. Transplant Cell Ther. 2021;27(3):222–9. https://doi.org/10.1016/j.jtct.2020.10.002
8. Hayden P, Gagelmann N, Snowden J. Long-Term Follow-Up and Late Effects. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H. (eds.) The EBMT/EHA CAR-T Cell Handbook. Cham: Springer; 2022. p.183–7. https://doi.org/10.1007/978-3-030-94353-0_36
9. Rotz SJ, Bhatt NS, Hamilton BK, Duncan C, Aljurf M, Atsuta Y, et al. International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update. Transplant Cell Ther. 2024;30(4):349–85. https://doi.org/10.1016/j.jtct.2023.12.001
10. Youssef E, Weddle K, Zimmerman L, Palmer D. Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up. Drug Safety. 2026;49:27–53. https://doi.org/10.1007/s40264-025-01596-9
11. Ellard R, Kenyon M, Hutt D, Aerts E, Ruijter M, Chabannon C, et al. The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities. Clin Hematol Int. 2022;4(3):75–88. https://doi.org/10.1007/s44228-022-00004-8
12. Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297–316. https://doi.org/10.3324/haematol.2019.229781
13. Cordeiro AC, Durisek G, Batista MV, Schmidt J, Lima M, Bezerra E. Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Front Oncol. 2024;14:1404351. https://doi.org/10.3389/fonc.2024.1404351
14. Ribeiro AAF. Follow-up beyond 1 month after autologous CAR T cell therapy. J Bone Marrow Transp Cell Ther. 2022;3(2):181. https://doi.org/10.46765/2675-374X.2022v3n2p181
15. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin JR, Hagemeister FB, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2020;106(10):2667–2672. https://doi.org/10.3324/haematol.2020.254045
16. Alizadeh A, Hamilton M, Phillips N, Noordenbos T, Boegeholz J, Sugio T, et al. CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. Research Square [Preprint] 2025. https://doi.org/10.21203/rs.3.rs-7746241/v1. [Accessed 13 Sep 2026].
17. Wang J, Peng H, Wang J, Li F. New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies. Exp Hematol Oncol. 2024;13(1):110. https://doi.org/10.1186/s40164-024-00573-9
18. Rejeski K, Jain MD, Shah NN, Perales M-A, Subklewe M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. The Lancet Haematology. 2024;11:e459–70. https://doi.org/10.1016/S2352-3026(24)00077-2
19. Giguère P, Akbarian N, Prince C, Thavorn K, Cieniak C, Granger M, et al. Late Immune Effector Cell Associated Hematologic Toxicity After CD19 CAR-T Therapy: Incidence, Clinical Course, and Resource Utilization. Eur J Haematol. 2026;116(5):596–603. https://doi.org/10.1111/ejh.70103
20. Hamilton M, Phillips N, Lee D, Ehlinger Z, Kramer AM, Srinagesh H, et al. Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms. Blood. 2024;144(S1):96. https://doi.org/10.1182/blood-2024-205378
21. Rejeski K, Subklewe M, Locke FL. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology Am Soc Hematol Educ Program 2023;2023(1):198–208. https://doi.org/10.1182/hematology.2023000472
22. Topp M, Feuchtinger T. Management of Hypogammaglobulinaemia and B-Cell Aplasia. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H. (eds.) The EBMT/EHA CAR-T Cell Handbook. Cham: Springer; 2022. p. 147–9. https://doi.org/10.1007/978-3-030-94353-0_28
23. Johnson G, Patel K, Arciola B, Perez AP, Wood A, Ionescu F, et al. Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia. Blood. 2023;142(S1):3512. https://doi.org/10.1182/blood-2023-185097
24. Melody M, Epperla N, Shouse GP, Romancik JT, Moyo TK, Kenkre VP, et al. Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma. Blood. 2023; 142 (S1):1738. https://doi.org/10.1182/blood-2023-183011
25. Frost BF, Frey N, Hexner EO, Schuster SJ, Nasta SD, Loren AW, et al. Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy. Blood. 2024;144(S1):588. https://doi.org/10.1182/blood-2024-204197
26. Tix T, Subklewe M, von Bergwelt‐Baildon M, Rejeski K. Survivorship in CAR T-cell Therapy Recipients: Infections, Secondary Malignancies, and Non-Relapse Mortality. Oncol Res Treat. 2025;48(4):212–4. https://doi.org/10.1159/000542631
27. Santos DMC, Tix T, Shouval R, Gafter-Gvili A, Alberge J-B, Cliff ERS, et al. A systematic review and metaanalysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30:2667–78. https://doi.org/10.1038/s41591-024-03084-6
28. Riedel A, Weller JF, Phely L, Hug S, Faul C, Lengerke C, et al. Long-Term Immunological Consequences of CD19 CAR T Cell Therapy: Analysis of Infectious Complications and Immune Reconstitution. Blood. 2024;144(S1):7248. https://doi.org/10.1182/blood-2024-210536
29. Ma S‐R, Bindal P, Trottier C, Elavalakanar P, Dodge L, Logan EK, et al. Late Infectious Complications of Chimeric Antigen Receptor T-Cell Therapy Beyond One Year. Blood. 2024;144 (S1):7789. https://doi.org/10.1182/blood-2024-209567
30. Ahmed N, Oluwole O, Mahmoudjafari Z, Suleman N, McGuirk JP. Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy. Clinical Hematology International. 2024;6(2):31–45. https://doi.org/10.46989/001c.115932
31. Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136(8):925–35. https://doi.org/10.1182/blood.2019004000
32. McArthur EM. Long-term neurocognitive effects of chimeric antigen receptor T-cell therapy: Integrating assessments into nursing practice. CanOncolNursJ. 2024;34(3):293–7. https://doi.org/10.5737/23688076343293
33. Graham CE, Velasco R, Tomas AA, Stewart OP, Dachy G, del Bufalo F, et al. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol. 2025;26(4):E203–13. https://doi.org/10.1016/S1470-2045(24)00715-0
34. Kuznetsova V, Oza H, Rosenfeld H, Sales C, van der Linde S, Roos I, et al. Cognitive and Psychological Recovery from the Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Blood. 2024;144(S1):7240. https://doi.org/10.1182/blood-2024-202851
35. Ho M-H, Cheung DST, Wang T, Wang L, Wong JWH, Lin C-C. Cancer-related cognitive impairment in patients with hematologic malignancies after CAR T cell therapy: a systematic review and meta-analysis of prevalence. Supportive Care in Cancer. 2025;33:312. https://doi.org/10.1007/s00520-025-09356-2
36. Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, et al. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology. 2021; 18(6): 363–78. https://doi.org/10.1038/s41571-020-00456-y
37. Cohen AD, Parekh S, Santomasso BD, Pérez-Larraya JG, van Donk NWCJ, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32. https://doi.org/10.1038/s41408-022-00629-1
38. Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099–2103. https://doi.org/10.1038/s41591-021-01564-7
39. Nagarajan JS, Mohammed A, Srikanth S, Subramanian L, Desai R, Jain A. Abstract 4366751: Long-Term Risk of Major Adverse Cardiovascular Events in Hematologic Malignancy Patients Treated with CAR-T Therapy: A TriNetX Propensity-Matched Cohort Analysis. Circulation. 2025;152(Suppl_3):A4366751. https://doi.org/10.1161/circ.152.suppl_3.4366751
40. Camilli M, Maggio L, Tinti L, Lamendola P, Lanza GA, Crea F, et al. Chimeric antigen receptor-T cell therapy related cardiotoxicity in adults and children cancer patients: A clinical appraisal. Front Cardiovasc Med. 2023;10:1090103. https://doi.org/10.3389/fcvm.2023.1090103
41. Dalal P, Patel N, Feinstein MJ, Akhter N. Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions. Technology in Cancer Research & Treatment. 2022;21. https://doi.org/10.1177/15330338221132927
42. Kramer AM, Baird JH, Srinagesh HK, Egeler E, Levine K, Brown A, et al. CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up. Blood. 2024;144(S1):69. https://doi.org/10.1182/blood-2024-198544
43. Little JS, Tandon M, Hong JS, Nadeem O, Sperling AS, Raje N, et al. Respiratory Infections Predominate after Day 100 following B-Cell Maturation Antigen-Directed CAR T-cell Therapy. Blood Adv. 2023; 7(18)5485–95. https://doi.org/10.1182/bloodadvances.2023010524
44. Yates B, Hoang C, Little L, Foley T, Epstein M, Shalabi H, et al. Long-Term Follow up Post CAR T-Cell Therapy in Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia. Transplantat Cell Ther. 2024:30 (2suppl):S340–1. https://doi.org/10.1016/j.jtct.2023.12.473
45. Ikeda D, Nawada T, Kondo T, Shinohara T, Nagano T, Kubota S, et al. Late-Onset Invasive Aspergillosis With Pituitary Involvement and Dysfunction Following CD19 Chimeric Antigen Receptor T-Cell Therapy. eJHaem. 2025;6(5):e70138. https://doi.org/10.1002/jha2.70138
46. Park JJ, Nguyen CV, Choi JN, Guitart J. Chimeric antigen receptor T-cell therapy-related T-cell malignancies: raising awareness of cutaneous manifestations. Br J Dermatol. 2025;193(6):1232–3. https://doi.org/10.1093/bjd/ljaf297
47. Shahzad M, Qasim H, Ponvilawan B, Amin MK, Zulfiqar F, Ismail A, et al. Second Primary Malignancies after CAR T-Cell Therapy: A Systemic Review. Blood. 2024;144(S1):7237. https://doi.org/10.1182/blood-
2024-198825
48. Ligon JA, Fry A, Maher JY, Foley T, Silbert S, Yates B, et al. Fertility and CAR T-cells: Current practice and future directions. 2022;28(9):605.e1–605.e8. https://doi.org/10.1016/j.jtct.2022.06.002
49. Buro AW, Gatell VI, Fulton HJ, Blackwell R, Zambrano KM, Rodriguez Y, et al. Sexual Health in Young Adult Patients after Chimeric Antigen Receptor T-Cell Therapy. Blood. 2023;142(S1):7378. https://doi.org/10.1182/blood-2023-178242
50. Schoemans H, Bolanos N, Warwick L. What do Patients Want? The Importance of Patient-reported Outcomes. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H. (eds.) The EBMT/EHA CAR-T Cell Handbook. Cham: Springer; 2022. p. 235–7. https://doi.org/10.1007/978-3-030-94353-0_47
51. Vasilj T, Holtzman NG, Pavletić S. CAR T Cell Therapy in Hematology: Navigating Toxicities and Deciphering Patient Experiences Through Patient-Reported Outcomes. Rad Medical Sciences. 2023; 559 (64–65):70–83. https://doi.org/10.21857/yl4okf5lg9
52. Pennings ERA, Spanjaart AM, Thielen FW, Oerlemans S, Fleischer A, Sanges C, et al. Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe. Blood Adv. 2025;9(24):6380–93. https://doi.org/10.1182/bloodadvances.2025017081
53. Alya P, Colin F, Charton E, Guibert S, Ysebaert L, Manson G, Daufresne P, et al. Remission after car t‐cells: do patients recover a normal life?. Hematological Oncology. 2023;41(S2):786–7. https://doi.org/10.1002/hon.3165_635
54. O’Shea PG, Johnson PC, El‐Jawahri A, LeBlanc TW. Unmet needs and lived experience of patients receiving CAR T-cell therapy. Leukemia & Lymphoma. 2025;66(6):1010–20. https://doi.org/10.1080/10428194.2025.2455488
55. Colin F, Bellec A, Bars LL, Granger M, Lucas LM, Ricard T, et al. Remote monitoring of CAR T-cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program. Research Square [Preprint] 2024. https://doi.org/10.21203/rs.3.rs-3937178/v1. [Accessed 13 Sep 2026].
56. Gazeau N, Beauvais D, Tilmont R, Srour M, Ferrant E, Safar V, et al. Myeloid Neoplasia after CD19 Directed CAR-T Cells: Cumulative Incidence, Risk Factors and Outcome. Blood. 2024;144(S1):2079. https://doi.org/10.1182/blood-2024-208851
57. Hammond D, Sasaki K, Takahashi K, Shpall EJ, Popat U, Oran B, et al. Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies. Blood. 2024;144(S1):1837. https://doi.org/10.1182/blood-2024-206801
58. Díaz JR, Dahiya S, Sillito FE, O’Reilly M, Rejeski Kai, Buecklein VL, et al. Cohort Comparison of Therapy-
Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies. Blood. 2024;144(S1):7239. https://doi.org/10.1182/blood-2024-201666
59. Farina M, Galli E, Riva M, Cutini I, Bernardi S, Martino M, et al. Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study. Blood. 2024; 144(S1): 4797. https://doi.org/10.1182/blood-2024-207660
60. Waldschmidt J, Merz M, Hecker JS, Reinhard F, Shibru BGT, Hoegner M, et al. Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy. Blood. 2024;144(S1):4688. https://doi.org/10.1182/blood-2024-210233
61. Gurney ME, Alkhateeb HB, Shah S, Bansal R, Hathcock M, Rosenthal A, et al. S263: cytopenias, age and car-hematotox score predict the development of post car t-cell therapy-related myeloid neoplasms. HemaSphere. 2023;7(S3):e6718317. https://doi.org/10.1097/01.HS9.0000967964.67183.17
62. Shi WJ, Wang H-Y. A Comprehensive Review of T-Cell Lymphoma Following CAR T-Cell Immunotherapy. Blood Adv. 2026;10(20):6981–6990. https://doi.org/10.1182/bloodadvances.2026021166
63. Aleman A, Oekelen O, Melnekoff DT, Grossman L, Mouhieddine TH, Kurowski A, et al. Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy. The New England Journal of Medicine. 2025;393(8):823–5. https://doi.org/10.1056/NEJMc2504588
64. Cho H, Lunney N, Maiti K, Otašević V, Learn C. Temporal Association and Risk Window for Secondary Malignancies Post CAR-T. Blood. 2024;144(S1):610. https://doi.org/10.1182/blood-2024-209058
65. Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, et al. Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. JCI Insight. 2021; 6(11):e146743. https://doi.org/10.1172/jci.insight.146743
66. Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, et al. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study. Journal for ImmunoTherapy of Cancer. 2021;9(10):e003428. https://doi.org/10.1136/jitc-2021-003428
67. Ozog S, Krantz EM, Tindbaek K, Munoz J, Liu WL, Chalal C, et al. Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response. Nat Commun. 2026; 17: 4924. https://doi.org/10.1038/s41467-026-71473-1
68. Zama D, Pedretti L, Capoferri G, Forestiero R, Lanari M, Esposito S. Immunization Strategies in Pediatric Patients Receiving Hematopoietic Cell Transplantation (HCT) and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Challenges and Insights from a Narrative Review. Vaccines. 2025;13(9):932. https://doi.org/10.3390/vaccines13090932
69. Styczyński J, Styczyński T, Sadlok J, Magdalena W, Rutkowska D. Vaccinations following CAR-T cell therapy: summary of reported cases and state-of-the-art review of current recommendations. Acta Haematol Pol 2022;53(3):207–14. https://doi.org/10.5603/AHP.a2022.0025
70. Reynolds G, Hall VG, Teh BW. Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy. Transplant Infectious Disease. 2023;25(S1):e14109. https://doi.org/10.1111/tid.14109
71. Sociedade Brasileira de Imunizações (SBIm). Calendário de vacinação: pacientes especiais 2026/2027 [Internet]. São Paulo: SBIm; 2026. https://sbim.org.br/calendario-de-vacinacao/pacientes-especiais [Accessed 13 Sep 2026].
72. Faramand RG, Xie Z, Jain MD. Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. J Clin Oncol 2026;44(8):698–708. https://doi.org/10.1200/JCO-25-02087
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Giancarlo Fatobene, Karine Sampaio Nunes Barroso

This work is licensed under a Creative Commons Attribution 4.0 International License.
